Navigation Links
Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
Date:10/20/2008

EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that the Company will host an investor conference call and webcast on Wednesday, October 22 at 4:30 PM Eastern Time to present an analysis of the data from the Isolagen Therapy(TM) Phase III pivotal studies (IT-R-005 and IT-R-006) for the treatment of nasolabial folds, or wrinkles. On August 5, 2008, Isolagen reported positive top-line efficacy and safety results from these two studies, which met all primary endpoints and were highly statistically significant.

The call participants will include Declan Daly, Isolagen's CEO, Dr. Stacy Smith, the Principal Investigator in the Phase III wrinkle studies and Co-Principal Investigator in the Phase II/III acne study, and Dr. Jeanne Novak, Clinical and Regulatory advisor to Isolagen.

A live webcast of the presentation will be accessible on http://www.isolagen.com. To participate in the audio portion of the call, dial 1-800-299-0433 and enter passcode 78803320. An archived replay of the conference call and webcast will be available for 90 days on http://www.isolagen.com or by dialing 1-888-286-8010 and entering passcode 63040312.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in Item 1A. "Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isolagen to Present at the JMP Securities Healthcare Focus Conference
2. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
4. Pharmaxis Investor Conference Call
5. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
6. The Michigan Life Sciences Pipeline Announces The Funding Place(TM) and Other Resources to Connect Investors and Startups
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
8. Halozyme Therapeutics to Host Research Day for Investors and Analysts
9. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
10. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2016)... , May 18, 2016 ... 2.0 prefilled pen following approval by EMA, the European ... leading science and technology company, the new pen version ... an increased level of confidence to patients during use. ... GONAL-f® prefilled pen easier to handle with a larger ...
(Date:5/17/2016)... ... May 17, 2016 , ... PATH and Laerdal ... collaborate to bring a feeding cup to market based on a reference design ... Center at Seattle Children’s Hospital, thereby ensuring an innovative feeding option for the ...
(Date:5/17/2016)... ... , ... A new study on mesothelioma trends in Sweden indicates that there ... Mesothelioma has just posted an article on the new research. Click here to ... kidney cancer seem to be more susceptible to mesothelioma, the researchers still aren’t sure ...
(Date:5/17/2016)... ... May 17, 2016 , ... New tests that go beyond the standard ... specific information that both the patient and doctor want and need to know in ... the American Urological Association’s annual meeting in San Diego, involve using blood, urine and ...
Breaking Biology Technology:
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
Breaking Biology News(10 mins):